RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Официальное название

Disitamab Vedotin Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer With HER2 Overexpression: a Prospective, Phase II Study

Обзор

This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery. The study drugs include RC48, Adebrelimab, Apatinib and S-1. The purpose is to evaluate the effectiveness and safety of the combined coordinated treatment of multi-mechanism drugs for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.

Подробное описание

The study plans to enroll 32 subjects. After signing the informed consent form and meeting the inclusion and exclusion criteria, patients will receive standard-dose treatment of the RC48, Adebrelimab, Apatinib and S-1 regimen for 3-4 cycles (every 3 weeks) before surgery. Apatinib will only be used for 14 days in the last cycle. Imaging studies will be conducted 3-4 weeks after the last dose to assess the efficacy of neoadjuvant therapy and the possibility of radical D2 gastrectomy. The treatment plan after curative surgery for gastric cancer will be determined by the investigators and the patients based on the pathological findings. Patients who benefit clinically after surgery may receive adjuvant therapy with RC48, Adebrelimab, Apatinib and S-1 for 4 cycles (the first treatment is expected to start around 4 weeks after surgery) or follow the standard postoperative adjuvant regimen recommended by the guidelines.

Вмешательства

• Препарат RC48
  RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
• Препарат Adebrelimab
  Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
• Препарат Apatinib
  Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
• Препарат S-1
  S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);

Первичные конечные точки

• Pathological Complete Response Rate (pCR) [Срок оценки: 4 months]

Вторичные конечные точки (4)

• Major Pathological Response rate (MPR) [Срок оценки: 4 months]
• R0 Resection rate [Срок оценки: 4 months]
• Disease-Free Survival (DFS） [Срок оценки: 24 months]
• Overall Survival (OS) [Срок оценки: 36 months]

Критерии участия

Критерии включения

• 1\. Participants voluntarily join this study, are able to complete the signing of the informed consent form, and have good compliance;
• 2\. Age between 18 to 75 years old (at the time of signing the informed consent form), with no gender restrictions;
• 3\. Gastrointestinal cancer or gastroesophageal junction adenocarcinoma confirmed by histology and/or cytology, diagnosed as locally advanced according to the 8th edition of the AJCC standards, with a cTNM diagnosis of T3-4aN+M0 and T4aNanyM0 based on ultrasound endoscopy or enhanced CT/MRI scan (and diagnostic laparoscopy if necessary), and agree to receive curative surgical treatment, with the investigator assessing the potential for tumor resectability;
• 4\. Have not previously received systemic treatment for the current disease, including anti-tumor chemotherapy/immunotherapy, etc.;
• 5\. HER2 overexpression confirmed by IHC results from endoscopic biopsy tissue (defined as: IHC 2+, 3+);
• 6\. ECOG score of 0-1;
• 7\. Estimated life expectancy of ≥6 months;
• 8\. Good major organ function:

Критерии исключения

• 1\. Concurrent malignant disease other than gastric cancer (excluding early-stage tumors that have been radically treated);
• 2\. Tumor lesions with a tendency to bleed (such as active ulcerative tumor lesions with positive fecal occult blood test, history of hematemesis or melena within 2 months before signing the informed consent form, or assessed by the investigator as being at risk of significant gastrointestinal hemorrhage, etc.) or having received blood transfusion treatment within 4 weeks before the study medication; 3. Inability to take oral medication;
• 4\. Currently participating in another interventional clinical study treatment, or having received other investigational drugs or used investigational medical devices within 4 weeks before the first administration of the study medication;
• 5\. Has had systemic treatment required within 2 years before the first administration of the study medication;
• 6\. Known allogeneic organ transplantation (except for corneal transplantation);
• 7\. Known allergy to any medication used in this study;
• 8\. Peripheral neuropathy of grade ≥2;
• 9\. Known history of human immunodeficiency virus (HIV) infection (i.e., positive for HIV 1/2 antibodies);
• 10\. Active hepatitis B or C infection;
• 11\. Received live vaccines within 30 days before the first administration (Day 1 of Cycle 1);
• 12\. Pregnant or breastfeeding women;
• 13\. Presence of any severe or uncontrollable systemic disease.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Публикации

• Ding Y, Qian H, Liu H, Zhang J, Zhang X, Wei J, Chen X, Xu H. DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer. J Gastrointest Oncol. 2026 Feb 28;17(1):31. doi: 10.21037/jgo-2025-aw-959. Epub 2026 Feb 12. PMID 41816563

Идентификаторы

NCT: NCT06385873 · 2024-SR-233

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗